| [1] |
DENG Qiling, SONG Di, XI Kexin, XIE Xiaoting, WU Xiaoyan, ZHAO Wei.
Research on high-throughput detection of plasma cell-free DNA for targeted therapy-related genes screening and prognosis prediction in non-small cell lung cancer patients
[J]. China Oncology, 2025, 35(4): 355-364.
|
| [2] |
JIA Ruijie, SHI Zhiqiang, ZHANG Qi, LU Yongjin, ZHENG Junsheng, SUN Jing, BI Zhao, SUN Xiao, WANG Yongsheng, QIU Pengfei.
Research on the association of breast cancer patients’ prognosis with internal mammary sentinel lymph node biopsy
[J]. China Oncology, 2025, 35(4): 394-403.
|
| [3] |
XUE Jialei, LI Jianwei, GONG Yue, LIU Guangyu, LIU Zhebin.
Predicting delayed diagnosis rate of intraoperative rapid frozen section pathological examination for early-stage breast cancer: a real-world retrospective study
[J]. China Oncology, 2025, 35(4): 404-411.
|
| [4] |
LI Bin, TAO Zhonghua, HU Xichun.
Precision diagnosis and treatment of breast cancer in the post-CDK4/6 inhibitor era
[J]. China Oncology, 2025, 35(3): 273-282.
|
| [5] |
ZHAO Kaile, WANG Lei, GENG Jianxiong, CUI Chengwei, YU Yan.
Research status and prospects of treatment for malignant pleural mesothelioma
[J]. China Oncology, 2025, 35(3): 326-332.
|
| [6] |
LU Yufeng, WANG Han, XIE Yifan, JIANG Yizhou, SHAO Zhimin.
Significant fundamental translational research on breast cancer in China: progress and prospects
[J]. China Oncology, 2025, 35(2): 143-153.
|
| [7] |
LIN Jialin, WANG Wenna, XU Binghe.
Current status and future perspectives of antibody-drug conjugates in breast cancer therapy
[J]. China Oncology, 2025, 35(2): 154-166.
|
| [8] |
ZENG Cheng, WANG Yuanyi, WANG Jiani, MA Fei.
Advances in immune checkpoint inhibitor therapy for breast cancer: research progress and future directions
[J]. China Oncology, 2025, 35(2): 195-204.
|
| [9] |
LI Junjie.
Progress and future prospects in local and systemic treatment of early breast cancer
[J]. China Oncology, 2025, 35(2): 205-212.
|
| [10] |
WANG Qing, YU Yushuai, WANG Chenxi, JIANG Zirong, LI Jialu, TANG Shicong, SONG Chuangui.
Current status and prospects of tertiary lymphoid structure heterogeneity in predicting response to neoadjuvant therapy and characterizing immune microenvironment in triple-negative breast cancer
[J]. China Oncology, 2025, 35(2): 213-218.
|
| [11] |
LAN Yu, WANG Fenghua.
Comparison and review of updated guidelines for advanced gastric cancer diagnosis and treatment in 2024: CSCO, NCCN and ESMO
[J]. China Oncology, 2025, 35(2): 219-227.
|
| [12] |
LU Yongjin, SHI Zhiqiang, LI Tong, WANG Yongsheng, QIU Pengfei.
Retrospective study on regional lymph node radiotherapy after axillary dissection exemption in breast cancer patients with sentinel lymph node positive status
[J]. China Oncology, 2025, 35(2): 228-236.
|
| [13] |
LI Yuan, GUO Lingchuan, YUAN Yong, ZHENG Qiang, JIN Yan, MING Jian.
Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with non-small cell lung cancer in China
[J]. China Oncology, 2025, 35(2): 237-248.
|
| [14] |
CAI Shuyue, XIE Quan, ZHOU Yuxuan, LIU Qingzhu, QIU Ling, LIN Jianguo.
Latest progress and prospect of NRP-1 targeted molecular probes for breast cancer diagnosis
[J]. China Oncology, 2025, 35(2): 249-254.
|
| [15] |
ZHAO Yihan, LI Ruochen, LIN Yansong.
Current status and prospect of diagnosis and treatment of bone metastasis of thyroid cancer
[J]. China Oncology, 2025, 35(1): 12-20.
|
